Notice for palopegteriparatide (Specialised Therapeutics Pharma Pty Ltd)
Active ingredients
palopegteriparatide
Date of review outcome
Lapse date
Type
Priority review
Indication
A prodrug providing sustained release of parathyroid hormone (PTH(1-34)), is a PTH replacement therapy indicated for the treatment of hypoparathyroidism in adults
Therapeutic area
Endocrinology